AI Article Synopsis
- There is limited information about the effects of paternal drug exposure at conception, which is the focus of the Motherisk Program established in 1985 for drug safety during pregnancy.
- Between 2002 and 2007, out of 188,188 counselling requests, only 301 (0.16%) were related to paternal exposure, with queries often about specific drugs like methotrexate and finasteride.
- The low number of inquiries highlights the necessity for more accessible information regarding paternal drug exposure and its potential implications.
Article Abstract
Background: There is a dearth of information on paternal drug exposure at the time of conception. The Motherisk Program, established in 1985, is a teratology information and clinical consultation service on drug safety during pregnancy and lactation, as well as paternal exposure (PEx). Here, we reviewed for the first time our experience with PEx.
Methods: This was an observational retrospective cohort study using a prospectively collected database. Telephone counselling records from January 2002 to December 2007, inclusive, were screened to identify cases concerning PEx.
Results: Of a total of 188,188 counselling requests over these 6 years, 301 (0.16%) pertained to PEx. Counselling was most frequently sought on methotrexate, finasteride, prednisone and azathioprine. For many drugs, limited or no information was available on PEx.
Conclusions: Paternal exposure represents a small fraction of counselling requests to Motherisk. Our findings suggest that there is an ongoing need for information on paternal drug exposure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.reprotox.2010.01.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!